| Natural innate and adaptive immunity to cancer MD Vesely, MH Kershaw, RD Schreiber, MJ Smyth Annual review of immunology 29, 235-271, 2011 | 2667 | 2011 |
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens MM Gubin, X Zhang, H Schuster, E Caron, JP Ward, T Noguchi, Y Ivanova, ... Nature 515 (7528), 577-581, 2014 | 2130 | 2014 |
| Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting H Matsushita, MD Vesely, DC Koboldt, CG Rickert, R Uppaluri, VJ Magrini, ... Nature 482 (7385), 400-404, 2012 | 1414 | 2012 |
| Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy MD Vesely, RD Schreiber Annals of the New York Academy of Sciences 1284 (1), 1-5, 2013 | 420 | 2013 |
| Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis JB Swann, MD Vesely, A Silva, J Sharkey, S Akira, RD Schreiber, ... Proceedings of the National Academy of Sciences 105 (2), 652-656, 2008 | 402 | 2008 |
| Resistance mechanisms to anti-PD cancer immunotherapy MD Vesely, T Zhang, L Chen Annual review of immunology 40, 45-74, 2022 | 174 | 2022 |
| T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma AX Lozano, AA Chaudhuri, A Nene, A Bacchiocchi, N Earland, MD Vesely, ... Nature medicine 28 (2), 353-362, 2022 | 163 | 2022 |
| Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state MWL Teng, MD Vesely, H Duret, N McLaughlin, JE Towne, RD Schreiber, ... Cancer research 72 (16), 3987-3996, 2012 | 154 | 2012 |
| A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy MF Sanmamed, X Nie, SS Desai, F Villaroel-Espindola, T Badri, D Zhao, ... Cancer discovery 11 (7), 1700-1715, 2021 | 100 | 2021 |
| PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus X Han, MD Vesely, W Yang, MF Sanmamed, T Badri, J Alawa, ... Science translational medicine 11 (522), eaax1159, 2019 | 89 | 2019 |
| Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis MJ Murphy, JM Cohen, MD Vesely, W Damsky Journal of the American Academy of Dermatology 86 (5), 1080-1091, 2022 | 73 | 2022 |
| Cancer Immunoediting in the Era of Immuno-oncology MM Gubin, MD Vesely Clinical Cancer Research 28 (18), 3917-3928, 2022 | 59 | 2022 |
| Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas J Yeung, V Yaghoobi, D Miyagishima, MD Vesely, T Zhang, T Badri, ... Neuro-oncology 23 (11), 1922-1935, 2021 | 37 | 2021 |
| Focus: skin: cutaneous lupus erythematosus: current and future pathogenesis-directed therapies AJ Little, MD Vesely The Yale Journal of Biology and Medicine 93 (1), 81, 2020 | 37 | 2020 |
| Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib WE Damsky, MD Vesely, AI Lee, J Choi, AC Meyer, M Chen, T Ahmad, ... JAAD case reports 5 (12), 1018-1026, 2019 | 31 | 2019 |
| Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis MD Vesely, S Imaeda, BA King JAAD case reports 3 (1), 4-6, 2017 | 30 | 2017 |
| Stimulating T cells against cancer with agonist immunostimulatory monoclonal antibodies X Han, MD Vesely International review of cell and molecular biology 342, 1-25, 2019 | 29 | 2019 |
| In silico analysis of the immunological landscape of pituitary adenomas JT Yeung, MD Vesely, DF Miyagishima Journal of neuro-oncology 147, 595-598, 2020 | 25 | 2020 |
| Cytokine RNA in situ hybridization permits individualized molecular phenotyping in biopsies of psoriasis and atopic dermatitis A Wang, AL Fogel, MJ Murphy, G Panse, MK McGeary, JM McNiff, ... JID Innovations 1 (2), 100021, 2021 | 22 | 2021 |
| Normalization cancer immunotherapy for melanoma MD Vesely, L Chen Journal of Investigative Dermatology 140 (6), 1134-1142, 2020 | 19 | 2020 |
Robert SchreiberWashington University School of Medicine在 immunology.wustl.edu 的电子邮件经过验证
